Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell by Poelstra, Klaas
 
 
 University of Groningen
Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell
Poelstra, Klaas
Published in:
Current Tissue Microenvironment Reports
DOI:
10.1007/s43152-020-00004-x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Poelstra, K. (2020). Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell. Current
Tissue Microenvironment Reports, 1, 13-22. https://doi.org/10.1007/s43152-020-00004-x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
CHRONIC LIVER DISEASE (M FERNANDEZ, SECTION EDITOR)
Innovative Nanotechnological Formulations to Reach the Hepatic
Stellate Cell
Klaas Poelstra1
# The Author(s) 2020
Abstract
Purpose of Review Treatment of liver fibrosis benefits from hepatic stellate cell (HSC)-specific delivery. Since the description of
first carrier to HSC, many developments have taken place in this area. The purpose is to give an overview of the different carriers
and homing moieties that are available for HSC targeting and illustrate the opportunities and hurdles they provide.
Recent Findings There is a growing number of homing devices to deliver drugs to HSC, and options to deliver siRNA to HSC
have emerged. Other developments include controlling corona formation, development of linker technology, and design of
theranostic approaches. We are on the eve of reaching the clinic with innovative HSC-specific compounds.
Summary An overview of different core molecules is presented together with an overview of targeting strategies toward different
receptors on HSC, providing a versatile toolbox. Many therapeutics, ranging from small chemical entities and proteins to RNA-
or DNA-modulating substances, have already been incorporated in these constructs in the recent years.
Keywords Liver fibrosis . Hepatic stellate cell . Drug targeting . Nanomedicine . Nanotechnology . Antifibrotic drugs
Introduction
Maybe a hundred years from now, people look back upon the
present times as the era when drugs were administered without
detailed control of their exact fate in the patient, and drugs
were given to patients using statistics to estimate beforehand
whether a person might benefit from that. Yet, times are
changing, and the number of innovative formulations that al-
low cell-specific delivery and facilitate personalized medicine
is rapidly expanding now. Today, many of these new cell-
specific approaches are focused upon the treatment of cancers.
Hundreds of monoclonal antibodies against many different
cancer cell types are now being tested in different phases of
(pre-)clinical trials (for review see [1, 2]). The treatment of
many types of neoplasms obviously benefits from a cell-
specific delivery of cell-killing or growth-arresting com-
pounds, but similar, the treatment of many chronic diseases
and in particular fibrotic diseases may also benefit from a cell-
specific delivery. Fibrotic diseases, with the exception of idi-
opathic pulmonary fibrosis, are slowly progressive processes
where several cell types and processes counterbalance each
other, leading to a very complex situation in vivo [3••, 4••],.
Many of the experimental antifibrotic drugs that perfectly
work within the target cell in vitro are ineffective in vivo,
either due to compensatory mechanisms or due to lack of
uptake in target cells. The clinical trials examining
Simtuzumab in patients with Primary Sclerosing Cholangitis
(PSC) [5, 6], and non-alcoholic steatohepatitis (NASH) [7] are
the most recent example of this. Clinical trials with this com-
pound were unsuccessful; either uptake in target cells was too
low [7] or the target of this antibody (lysyl oxidase-like protein
2) is not the (only) key player in disease progression [6].
Moreover, unlike the formation of tumors, tissue turnover
and repair are normal physiological processes that occur in
all normal tissues, leading to adverse effects of antifibrotic
drugs. Such off-target effects are not very well accepted for
chronic diseases in particular when the symptoms of the dis-
ease are not life-threatening yet, which is the case at the early
stages of liver fibrosis. The intrahepatic delivery of therapeu-
tics is therefore a key to treat diseases like liver fibrosis.
Surprisingly, only a very few monoclonal antibodies have
been tested to treat this disease, although there are many
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similarities with cancer [8]. Simtuzumab did reach clinical
trials, but this is a rare case, in contrast to the hundreds of
tumor-directed antibodies. Yet, to enhance delivery of drugs
in the target area, many other strategies have been developed
using a variety of drug carriers. The present review will focus
on these developments, with special focus on the different
drug carriers and targeting strategies that have been tested to
enhance uptake in hepatic stellate cells (HSC), the key target
cell for antifibrotic therapies.
Uptake of Drugs and Nanomedicines in the Liver
The liver contains several resident cell types that orchestrate
together normal homeostasis, synthesize important plasma pro-
teins and lipids, and take care of the clearance of metabolites,
toxins, or foreign particles. To that end in particular, hepato-
cytes are endowed with many different transporter proteins that
take up lipids, proteins, sugars, and chemical toxins [9, 10].
Uptake of plasma components by hepatocytes can occur by
passive diffusion but also by active transport via many different
transporters. Transporters on the sinusoidal site of hepatocytes,
such as several types of organic anion transporters (OATs),
organic cation transporters (OCTs), and the Na-Taurocholate
Co-Transporting Polypeptide (NTCP), transport a wide variety
of drugs from the blood into the hepatocyte through recognition
of their physico-chemical properties, such as charge and lipo-
philicity, with often a broad overlap in substrate specificity
(reviewed elsewhere [9, 10]. Next to these receptors, uptake
of plasma glycoproteins by hepatocytes can occur via several
lectin receptors such as the asialoglycoprotein receptor (ASGP-
R) [11], and in particular, the ASGP-receptor that binds galac-
tose residues has been applied in many studies to deliver pro-
teins or other drug carriers to hepatocytes [11] by decorating
core molecules with galactose or lactose moieties. However,
even without drug targeting strategies, most drugs are taken
up by the liver and uptake of these drugs mostly reflects uptake
by hepatocytes.
Kupffer cells (KC) are liver-specific macrophages that also
take up many different compounds. Compounds larger than
100 nm, foreign proteins, viruses, and bacterial products are
taken up either non-specifically, or specifically via Fc recep-
tors, complement receptors, the Coxsackie and adenovirus
receptor (CAR), several types of scavenger receptors and lec-
tin receptors like the mannose receptor [12, 13••], and other
pattern recognizing receptors (PAMPs) or damage-associated
membrane receptors (DAMPs) [14, 15]. In particular the man-
nose receptor [15] and scavenger receptors recognizing nega-
tively charged proteins [16, 17] have been extensively used
for cell-specific delivery of drugs to KC. KC represent ap-
proximately 80% of the total macrophage activity in the body
[18], [19] and are therefore responsible for the clearance and
immune presentation of most of the blood-born particles and
foreign proteins. Even long-circulating compounds that are
not immediately recognized by any uptake system eventually
may end up in KC and macrophages in the spleen where the
compounds are rapidly degraded. This has for instance been
demonstrated for PEGylated liposomes [18]. PEGylation of
compounds is done to induce enhance the half-life in plasma
thus creating a long-circulating compound. However, repeated
administrations of PEGylated compounds led to the acceler-
ated blood clearance (ABC) phenomenon [18]. Unravelment
of this phenomenon revealed evidence of macrophage activa-
tion by PEG liposomes and subsequent presentation of these
constructs to the immune system, which led to rapid clearance
from the blood [18]. Next to immune presentation, targeting to
Kupffer cells or any other macrophage in the body also con-
fers the risk of activating these macrophages thereby stimulat-
ing a local inflammatory process [14, 18, 19] or killing them
with serious effects on the immune system. Many of the large
constructs (> 100 nm) that are developed for drug-targeting
purposes to tumors or other diseases are taken up by KC,
eventually.
Sinusoidal endothelial cells (SEC) are aligning the sinu-
soids within the liver and via endothelial fenestrae (with
diameters of around 200 nm), and the space of Disse and
these SEC are exposed to plasma components on both
sides. Blood cells can act as a plunger (as in a syringe) in
the small sinusoids to push plasma via the fenestrae into the
space of Disse to further facilitate contact of plasma com-
ponents with hepatocytes, KC, and SEC. Together with the
macrophages, liver sinusoidal endothelial cells represent
the reticuloendothelial system (RES) [15, 20] that is re-
sponsible for the uptake of most large nanoparticles in the
blood [21]. SEC takes up lipids and proteins non-
specifically via transcytosis and pinocytosis mechanisms
and by endocytosis via specific receptors such as scavenger
receptors for negatively charged proteins [17, 22], and
hyaluronic acid receptors [23]. Scavenger receptors and
hyaluronic acid receptors have been frequently applied for
the cell-specific delivery of drugs to SEC [22, 23].
Another cell type within the liver is the cholangiocyte that
forms the bile ducts. These cells are important for the excre-
tion of bile acids and other electrolytes secreted by hepato-
cytes, but they generally do not play a role in the uptake and
intracellular processing of drugs or other plasma components.
Cholangiocytes do play an important role in PSC by the se-
cretion of proinflammatory and profibrogenic mediators that
activate HSC, the key drivers of fibrogenesis, which makes
them a target for antifibrotic therapies in particular for biliary
fibrosis but also in advanced stages of other fibrotic liver dis-
eases [4••, 24, 25]. The only known target receptor for drug
carriers to cholangiocytes is the αvβ6-integrin receptor [4••,
24, 26]. Several compounds that bind to this receptor to allow
delivery of drugs and imaging agents to cholangiocytes have
been prepared [4••]. A synthetic peptide against this αvβ6-
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receptor (FBA-A20FMDV2) is now being tested in a clinical
trial for imaging purposes (www.clinicaltrials.gov).
Last but not least, the liver contains hepatic stellate cells
(HSC), portal fibroblasts, and myofibroblast-like cells.
Fibroblasts are mostly located along bile ducts and blood ves-
sels, and HSC are located in the space of Disse, in the vicinity
of KC. In a quiescent state, these HSC store vitamin A [27]. In
an activated state, induced by cell-damage or by soluble fac-
tors from adjacent cells, these cells strongly proliferate, ac-
quire contractile elements, and become the major producers
of extracellular matrix proteins, such as collagens, fibronectin,
and laminin [27]. Fibroblasts and HSC play a key role in tissue
repair, and the progression of liver fibrosis and these cells are
therefore the main target cell for antifibrotic therapies.
However, resting or activated-HSC have no particular role in
the clearance or uptake of compounds from the circulation.
Resting HSC are therefore not endowed with prominent up-
take mechanisms, other than for vitamin A bound to retinol
binding protein [28], and they consequently do not take up
more drugs than any other random cell within the body. In
fact, a drug has more chance ending up in neighboring hepa-
tocytes, KC, or SLEC than in HSC. In the past years, several
cell-specific carriers to HSC have therefore been developed
directed at different receptors. The mannose-6-phosphate/in-
sulin-like growth factor II (IGFII) receptor was the first recep-
tor studied for this purpose [29], followed by the collagen type
VI receptor [30], and the PDGF-β-receptor [17, 31]. A mono-
clonal antibody against the synaptophysin receptor also has
been tested, but without follow-up [32], and in the recent
years, many studies have been published using the vitamin
A receptor upon HSC as target receptor for antifibrotic com-
pounds [33–37]. A lipid nanoparticle functionalized with vi-
tamin A and containing siRNA against heat shock protein 47
(HSP47) is now being tested in clinical phase 2 trials (www.
clinicaltrials.gov), which makes it the first cell-specific nano-
particle against liver fibrosis reaching clinical trials.
Cell-Specific Delivery
As outlined above, all resident hepatic cells can be selectively
reached by focusing on different target receptors and different
drug-carrier systems [17, 38, 39]. The relevance of each cell
type and hence the choice of the target and the carrier depends
on the liver disease. Antiviral hepatitis therapies or hepatopro-
tective drugs need to be directed at hepatocytes, whereas au-
toimmune diseases and other inflammatory disease require
uptake of drugs into Kupffer cells. Vasoactive compounds
need to be delivered to SEC, whereas for biliary diseases,
the cholangiocyte is the main target cell. The key target cell
for antifibrotic drugs is obviously the hepatic stellate cell.
Uptake by the wrong cell type makes drugs ineffective and
may lead to adverse effects, or even worse, may have the
contrary effect. For instance, whereas INFγ has significant
antifibrotic effects in HSC [40, 41], its potent proinflammato-
ry activities in macrophages create many pro-fibrotic stimuli
in vivo [42], [43]. Also, therapeutical approaches that focus on
apoptosis, survival, or induction of cell death of resident he-
patic cells [44••] face the issue that while increased survival of
hepatocytes may attenuate fibrogenesis, the very same effects
in other cells may stimulate liver fibrosis or tumorrigenesis
[44••, 45]. Also, the hepatotoxic effects of many tyrosine ki-
nase inhibitors limit the clinical application of these drugs [46]
despite their significant antifibrotic effects in HSC [46, 47].
Nanoparticles as Drug Carriers to Hepatic Cells:
Benefits and Key Problems
A drug-carrier construct basically consists of at least three
elements: a carrier (or core molecule), a homing device, and
a drug. In the case of a monoclonal antibody, these three ele-
ments are represented in one molecule, with the Fab fragment
as homing device and the therapeutic entity, the Fc region, and
complement binding moiety as additional therapeutically ef-
fective components, and the big core molecule of 150 kD (in
case of IgG) as structure that prevents renal clearance and
ensures a long circulating half-life. In some constructs, a forth
element is introduced: a linker or spacer between the drug
carrier and the drug. This linker may be necessary for a stable
binding of the drug to its carrier, or it is introduced to allow
release of active drugs at the site of action. The linker tech-
nology to couple drugs to monoclonal antibodies is an impor-
tant and rapidly evolving field [48, 49], but for other con-
structs such as liposomes this is less essential. Nevertheless,
all drug-carrier constructs are sophisticated molecules involv-
ing a lot of engineering. This engineering creates many oppor-
tunities but can make the synthesis of constructs also very
complex and costly and may introduce heterogeneity of the
final product. Moreover, most carriers are large entities that
confer the risk of uptake by macrophages and hence immuno-
genicity [38, 50]. A particular disadvantage of most drug-
carrier constructs is that the oral route of administration is
excluded. The development of delivery tools that create
sustained release of proteins from a subcutaneous depot [51]
may therefore be a valuable asset to address this problem. This
is in particular relevant for chronic diseases that require
prolonged treatment.
In the past decades, many other, non-antibody-based car-
riers have been explored. Studies have either examined virus-
es, liposomes, large proteins like albumin, antibodies, mi-
celles, lipoplexes, and nanoparticles based on synthetic poly-
mers, inorganic compounds such as gold and silica as drug
carriers (Fig. 1). Each carrier offers its own possibilities, ad-
vantages, and disadvantages.
Nanoparticles generally have a size of 10–150 nm and can
roughly be divided into two groups: organic and inorganic
nanoparticles. Organic nanoparticles carriers comprise protein
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complexes, liposomes, solid lipid nanoparticles (SNL) and
some polymers like polylactic acid (PLA) [52••]. Inorganic
nanoparticles comprise dendrimers, gold nanoparticles, iron
oxide quantum dots, polymers, carbon nanoparticles, and sil-
ica nanoparticles. Cell-specific delivery can be achieved by
functionalization of the surface of these particles, and this
approach has been applied in many studies in the recent years
to achieve HSC delivery. For instance, inorganic nanoparticles
like superparamagnetic iron oxide nanoparticles (SPIONs)
have been functionalized with relaxin to deliver relaxin to
HSC and simultaneously allow imaging of the target cell
[53•]. Polyamidoamine (PAMAM) G5 dendrimers have been
decorated with vitamin A to deliver an NO-donor to HSC
[54], whereas the same dendrimer has been coated with
RGD peptides to target the integrin αvβ3, which is also pres-
ent on HSC [55]. These are examples of active targeting,
where a compound is actively delivered to a designated target
receptor. However, in particular, the larger drug carriers make
use of passive targeting. In this case, accumulation in the
target area is achieved by the enhanced permeability retention
(EPR) effect [56]. The particle is not delivered to a designated
target cell using a homing device but passively accumulates at
the target area due to a local increase in vascular permeability
(for a schematic representation see Fig. 1). This increased
vascular permeability occurs during inflammatory processes
or during angiogenesis in tumors and some chronic diseases.
Following the extravasation of soluble plasma components,
the relatively large size of nanoparticles combined with the
low pressure in the interstitial space limits the return of such
particles into the bloodstream that causes local retention. The
“plunger effect” of blood cells (see above) may further add to
the extravasation of particles. Similarly, the large size of
pentameric IgM molecules (approximately 900 kD) leads to
passive entrapment of IgM molecules in the inflammatory
area, which is of course quite beneficial. For the treatment of
liver fibrosis, several carriers have been designed that make
use of this EPR effect. For instance, lipid nanoparticles (LNP)
carrying siRNA that inhibit the production of procollagen
α1(I) [57] or anti-col1α1 siRNA-loaded nanohydrogel parti-
cles [58]. Both carriers delivered siRNA to HSC in sufficient
amounts to attenuate collagen production in fibrotic mouse
models. However, passive accumulation in the target area
does not mean uptake in the proper target cell, and not all
diseases and tumors are characterized by a local enhanced
vascular permeability. In fact, although the liver with its small
sinusoids, its fenestrated endothelium and the open space of
Disse underneath the endothelium cells, is perfectly equipped
to create an EPR effect in normal physiological conditions,
during liver fibrosis, the whole situation changes.
Capillarization of sinusoids occurs during fibrosis which is
Fig. 1 Schematic representation of the liver architecture and three mechanisms of passive targeting to liver cells (left hand panel), and an overview of the
different core molecules, homing devices, and target receptors that are available for active delivery of therapeutic entities to HSC (right hand panel). The
reports presented in this review make use of different passive targeting mechanisms and/or a combination of core molecules and homing devices to
achieve accumulation of antifibrotic compounds in hepatic stellate cells
HSC, hepatic stellate cell; KC, Kupffer cell; SEC, sinusoidal endothelial cell; Hep, Hepatocyte; RBC, red blood cell
Curr. Tissue Microenviron. Rep. (2020) 1:13–2216
associated with the closure of endothelial fenestrae and extra-
cellular matrix deposition in the space of Disse [4, 27]. Due to
this, the EPR effect will be hampered or even be blocked
during fibrogenesis, causing reduced uptake of nanocarriers
that make use of this EPR effect in the fibrotic liver [59].
The major advantage of larger nanoparticles is their pay-
load; in contrast to small drug carriers like proteins or antibod-
ies, they can incorporate high drug concentrations, and incor-
poration of drugs and additional compounds is rather easy.
There is in general no need for chemical coupling of drugs
to the carrier which ensures release of unmodified, pharmaco-
logically active drugs after uptake by its target cell. Moreover,
virtually, all drugs can be incorporated; lipophilic drugs can be
non-covalently incorporated in the solid lipid core of lipid
nanoparticles or in the lipid bilayer of liposomes or micelles
and hydrophilic drugs in the aqueous phase of liposomes or
micelles [60]. In contrast, small carriers like proteins and some
polymers require chemical conjugation of drug and carrier.
Not all drugs have a chemical entity that allows coupling,
and conjugation may also affect the pharmacological effects
of the drug or even the distribution of the carrier. Drugs incor-
porated in nanoparticles also do not alter the physico-chemical
properties of the carrier itself, thus ensuring that the disposi-
tion of the carrier is not affected by its cargo, which may be a
problem for instance when drug:IgG ratios are too high in
antibody-drug conjugates [48, 49]. Also, mixture of drugs
can be readily incorporated in large nanoparticles, allowing
multi-drug therapies, which may turn out to be quite important
for a complex disease like liver fibrosis. And last but not the
least, incorporation of imaging agents, together with the drug,
offers the option of a theranostic approach, that is, it opens
opportunities for treatment and target imaging at the same
time [61•].
However, a key problem for many types of nanoparticles is
the formation of a corona [62]. Corona formation involves the
opsonization of a nanoparticle with plasma components. All
kind of plasma proteins and lipids can accumulate into the
lipid bilayer of a liposome or may get non-covalently attached
to silica, gold, or other inert inorganic particles [63]. Recent
studies have shown that many different plasma proteins and
lipids are more or less selectively opsonized by a nanoparticle,
leading to an enrichment of certain proteins in the corona
during their circulation time [63]. This opsonization greatly
affects their body distribution: it can lead to enhanced uptake
in non-target cells such as the opsonization of complement
factor C3 into liposomes, leading to uptake in macrophages
[64], whereas the binding of apo-lipoproteins shifts the uptake
of nanoparticles to hepatocytes [15]. This corona formation
can thus disrupt all cell-selective targeting strategies. Current
research activities focus on the prevention of corona forma-
tion, e.g., by the coupling of PEG molecules to the liposomes
or other nanoparticles [65], although this may lead to other
problems such as the accelerated blood clearance
phenomenon (see above). Fundamental knowledge on pro-
cesses that affect corona formation is lacking, but it is becom-
ing clear that physio-chemical properties of the particle itself
are an important factor [62, 66]. The composition of plasma is
also of great importance [66] and obviously this changes dur-
ing disease, making it even more complicated. It is also be-
coming clear that the composition of the corona may affect the
intracellular routing of nanoparticles within cells [66].
Nanoparticles can be internalized and degraded within the cell
via clathrin- or caveolin-dependent pathways or other non-
selective routes, dependent on the properties of the nanoparti-
cle [67], and this will in turn affect the release profile and the
pharmacological effects of the released drugs within the cell
[67]. If more basic knowledge becomes available, strategies
may be developed to modify the corona in such a way that it
does not corrupt the delivery, yet even may be used to affect
body distribution leading to enhanced delivery into the target
area or cell. This strategy was applied in a recent study where
retinol-binding protein 4 (RBP4) and albumin were recruited
into the corona of a nanoparticle by using an amphiphilic
polymer of positively charged polyethylenimine (PEI) and
retinol [24]. Antisense oligonucleotides were also attached to
PEI. The RBP4-retinol-albumin complex subsequently
formed in plasma yielded a nanoparticle that effectively deliv-
ered antisense oligonucleotides in HSC in the CCL4-liver fi-
brosis model in mice [28], making in an elegant way use of
corona formation. A schematic representation of the three
mechanisms of passive targeting, with corona formation as
one of them, is presented in Fig. 1.
Proteins as Drug Carriers to HSC
Paul Ehrlich introduced the “magic bullet” concept already in
1906 by proposing to use antibodies to enhance the effective-
ness of antibiotics and to reduce their adverse effects, but it
took until the year 2000 for the first antibody-drug conjugate
(ADC) to reach the market, Gemtuzumab ozogamicin
(Mylotarg) for the treatment of CD33-positive acute myeloid
leukemia [49]. And even then, the construct was retracted in
2010 because of adverse effects. However, it was re-
introduced in 2017 [49]. To date, five ADCs are approved
by the FDA and EMA [49]; more are nowadays tested in
clinical trials, and hundreds of ADCs are in the experimental
or pre-clinical phase [49, 68] for antitumor therapies. A major
step in the development of ADC’s was obviously the human-
ization of antibodies, preventing immunogenic responses
against constructs, but the development of chemical linkers
was also essential to prepare effective ADC’s. Due to lack of
cell-specific targets for fibrotic diseases, no antibody-drug
conjugates are available to treat fibrosis. Although many cells
and cellular processes are derailed during fibrogenesis, the
cells involved are all endogenous cells, and matrix turnover
is a normal physiological process in all tissues. Cell-specific
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targets for monoclonal antibodies in fibrotic tissues remain to
be found.
Yet, a relative enhancement of target receptors upon HSC
appears to be equally applicable for drug-targeting purposes.
In fact, an antibody with high affinity for its target may in
these cases be less applicable than drug carriers with lower
affinity, because interaction with the target receptor needs not
to be maximal, but interaction with non-target cells needs to
be minimal. This is for instance true for the PDGFβ receptor
and the IGFII receptor, which are also expressed in other tis-
sues but whose expression is very strongly upregulated on
fibroblast-like cells during fibrogenesis, leading to a relatively
high local accumulation in HSC of carriers directed at these
receptors. Most likely, the high liver perfusion and an
(residual) EPR effect in fibrotic livers may also help.
Eventually, when cell-specific antibodies for fibrogenic cells
will be found, much advantage can be gained by the experi-
ences obtained in the cancer field [8]. Nanobodies, Fab frag-
ments, or other modifications of Ig can be explored. Major
problems specific for immunoglobulines include the limited
options these molecules offer to attach drugs and their low
payload to target cells. If a high drug-antibody ratio is obtain-
ed, it may significantly affect biodistribution and half-life of
the antibody [49]. However, this area is rapidly expanding
[48, 49, 68]. To allow stable coupling of drugs to
immunoglobulines and at the same time release of pharmaco-
logical active drugs after internalization in the target cell, new
linker strategies are now examined [48]. For instance, recent-
ly, a platinum-based linker XLS has been examined in several
studies using protein-based carriers to HSC as well, with suc-
cessful outcomes [47, 68].
Protein-based carriers, other than IgG, have been exten-
sively applied to deliver antifibrotic drugs to hepatic stellate
cells. Such carriers generally have a core protein, such as
human serum albumin, with a size high enough to prevent
renal clearance (> 65 kD) yet small enough to prevent uptake
by the reticuloendothelial system (< 100 nm). Albumin allows
a higher drug loading than IgG, Fab fragments, or nanobodies.
Modified proteins may also be subject to immunogenic re-
sponses of the host. Indeed, immunogenicity toward a drug-
carrier construct has been found in some studies in particular
when heterologous albumin was used as carrier [51]. The
change of human serum albumin into albumin derived from
mice was found to reduce immunogenicity of the constructs in
mice [51], but risks for prolonged treatment do exist in partic-
ular when sugar-moieties are used as homing device. Many
different types of drugs have been targeted to HSC in the past
decade (for an overview see [17, 39, 44••, 52••], but in recent
years, the cell-specific delivery of tyrosine kinase inhibitors
has been extensively explored, because of their significant
antifibrotic affects [47], paralleled by adverse effects [46].
Because most kinase inhibitors do not have a chemical entity
that allows covalent binding to its carrier, a linker between the
carrier and the drug has been developed [68]. These platinum-
based linkers have been applied in several studies to deliver
tyrosine kinase inhibitors to HSC and other cells with good
results in experimental animal models [47, 68].
Cell-Specific Delivery of Antifibrotic Drugs: Homing
Devices
The alternative approach is active targeting which involves the
coupling of homing moieties to the nanoparticle.
Nanoparticles functionalized with folate or antibodies are
well-studied constructs in the cancer field [69]. Focusing on
the last 5 years, several innovative strategies have been exam-
ined in the field of HSC targeting (summarized in Fig. 1). A
variety of liposomes have been engineered for the delivery of
antifibrotic drugs to HSC, sometimes even delivering more
than one drug at the same time. A number of receptor-
recognizing peptides have been developed to direct proteins
and nanoparticles to designated receptors on HSC. The first
HSC-specific carrier that used a cyclic peptide was directed at
the collagen type VI receptor [30], [70]. This RGD-based
peptide was coupled to albumin to yield a HSC-selective drug
carrier. Subsequently, a bicyclic peptide binding to the
PDGF-β-receptor was developed (pPB) [31] that rapidly ac-
cumulated in HSC. This pPBwas coupled to albumin to create
a HSC-specific drug carrier [31]. Recently, this carrier was
used to deliver the Rho-kinase inhibitor Y27632 to HSC lead-
ing to beneficial effects in vivo [47]. pPB has also been direct-
ly coupled to interferon γ to create a HSC-specific antifibrotic
cytokine [71], whereas other groups coupled this pPB peptide
to liposomes to deliver interferon γ to HSC [72]. The same
peptide was used to deliver lipid nanoparticles containing
siRNA to HSC [73]. In addition, a cyclic-RGD-based peptide
was coupled to liposomes for the delivery of the hedgehog
inhibitor vismodegib [74]. This latter construct was quite ef-
fective in reducing fibrosis in two experimental animal models
of liver fibrosis in mice. In recent years, another receptor-
recognizing peptide binding to the CXCR4 receptor has been
developed [75•] which was coupled to polymeric biodegrad-
able nanoparticles to create a carrier that allowed the simulta-
neous delivery of sorafenib and the MEK inhibitor
selumetinib to HSC [75•]. This combination therapy displayed
significant antifibrotic effects in a mouse model. The CXCR4
receptor was also used for the targeting of pirfenidone to HSC
[76•]. In this latter case however, the nanoparticles
(liposomes) were not functionalized with receptor-
recognizing peptides but with the CXCR4 antagonist
AMD3100 (plerixafor). The effect of pirfenidone, one of the
few FDA-approved drugs against fibrosis, combined with
blocking of the chemokine receptor CXCR4 may lead to syn-
ergistic effects and is another example of a successful combi-
nation therapy. Next to peptides and a receptor antagonist,
sugar moieties have been used as homing devices as well.
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Mannose-6-phosphate coupled to albumin [29], binding to the
IGF II-receptor has been used frequently for HSC-specific
delivery of drugs (for review see [17, 39]. Vitamin A-loaded
liposomes have gained much attention as HSC-specific car-
riers since the first publication by Sato et al. [33]. Using vita-
min A-decorated nanoparticles, recent studies showed suc-
cessful delivery to HSC of several compounds such as
siRNA and anti-miR33 [77], BMP4 siRNA [78], the Rho-
kinase inhibitor Y27632 [79], and Imatinib [37]. All these
different types of drugs in vitamin A-coated liposomes nicely
illustrate the versatility of liposomes as vehicles for drug de-
livery. Vitamin A has also been coupled to other nanoparticles
to achieve HSC-specific delivery of antifibrotic compounds:
next to the earlier mentioned dendrimers [54], chitosan-based
nanoparticles have been modified with vitamin A and loaded
with JQ1 and atorvastatin [80], both inhibiting HSC.
Other nanoparticle constructs that have been applied in
recent years to reach the HSC in vivo for the delivery of
antifibrotic drugs are carboxymethyl cellulose-based nanopar-
ticles for the delivery of docetaxel to HSC. These PEGylated
nanoparticles bind to serum albumin and the Secreted Protein
Acidic and Rich in Cysteine (SPARC) which induces uptake
in HSC and tumor cells [81], again a nice example of corona-
directed uptake in target cells. Dibutyltin dichloride (DBTC)-
based lipoplexes have been applied for the delivery of Foxf1
siRNA to HSC [82], and hyaluronic acid-based micelles have
been used for the delivery of the angiotensin I receptor
Losartan to the CD44 receptor on HSC [83]. Since these target
receptors are not specific for HSC, the cellular specificity of
these constructs need further examination.
Drugs to be Targeted
Next to small chemical entities with antifibrotic effects, that
have been coupled and incorporated in many of the above-
reviewed drug carriers, biological products like antisense oli-
gonucleotides, siRNA, miRNA, and cytokines can be power-
ful tools to modify fibrosis. The therapeutic applications of
siRNA have become clear in recent years, and many different
miRNA [84] and siRNA molecules [22, 33, 35, 58, 73, 78]
have been tested in experimental animal models of fibrosis.
Delivery is the key issue for siRNA and miRNA molecules.
Although cytokines play a key role in vivo in regulating
fibrogenesis and are active in the picomolar range, their pleio-
tropic activities have strongly limited their therapeutical use.
This may be solved using targeting strategies [71]. Also, the
use of the CRISPR/Cas9 site-specific nuclease system has
revolutionized the therapeutic options for several diseases,
and may also provide new opportunities for the treatment of
liver fibrosis. A recent study showing the antifibrotic effects of
the knock down of the glial cell line-derived neurotrophic
factor (GDNF) using the CRISPR/CAs9 in an adeno-viral
delivery system [85] illustrates an exciting development.
Because of this, the cell-specific delivery of biologicals has
gained growing attention in recent years. The delivery of bio-
logicals adds an additional set of requirements to their carriers
[38]. They need to be protected from degradation mechanisms
in plasma and in the target cell where the carrier constructs
following endocytosis mostly end up in lysosomes. The acidic
environment and proteolytic cleavage mechanisms in lyso-
somes are generally used to induce the release of chemical
entities from their carriers, but biologicals are being destroyed
there. For the delivery of genes, non-viral delivery systems
have been developed (reviewed elsewhere; [86]), which es-
cape from these degrading mechanisms, and viruses are also
equipped with mechanisms that allow delivery of their pay-
load to the nucleus, but toxicity, immunogenicity, transfection
efficiency, and other factors limit their application.
Nevertheless, tools are now available for the delivery of anti-
sense oligonucleotides, miRNA, and siRNA molecules [33].
Challenges lie ahead in the area of cell-specific delivery of
bioactive proteins. The CRISPR/Cas9 site-specific nuclease
system offers new very innovative options for treatment, but
requires an even more a sophisticated approach. In this re-
spect, the recent fundamental studies in intracellular traffick-
ing mechanisms of after the intracellular uptake of
nanomedicines [66] are very important. In recent years, some
studies have shown that cell-specific proteins can escape from
the intracellular degradation mechanisms: the delivery of
INFγ to the PDGF receptor is an example of this [71].
Maybe this offers opportunities for other cytokines as well.
Conclusions
It can be concluded that there are many different drug carriers
to reach the different hepatic cells, in particular the hepatic
stellate cell. This variety of carriers, each with their own ad-
vantages and disadvantages, offer a versatile toolbox for many
different drugs and biologicals. Particular biologicals like
siRNA and cytokines offer great opportunities for therapy
but they do need steering to the proper cells and protection
from endogenous clearing mechanisms. Liver fibrosis is a
complex disease with many redundant systems; either a drug
needs to be very potent or very pleiotropic or more than one
drug needs to be applied, similar to the current antiviral and
antitumor therapies. Developments in the field of
nanomedicines may provide the tools to do just that; as
outlined here, several studies have already shown that delivery
of more than one compound to the target cell is feasible.
Nanomedicines, including protein-based constructs, also offer
a theranostic approach where treatment and monitoring of
disease activity coincide. New advancements in this area have
been made for the treatment of liver fibrosis in animal models
[53•]. Tools for early diagnosis and monitoring of disease
activity are essential for the development of an effective
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therapy [87]. The strategy of cell-specific drug carriers may
thus remove major hurdles for antifibrotic therapies [88], i.e.,
low drug effectivity and adverse effects and also increase the
success rate of clinical trials by facilitating patient stratifica-
tion and providing new ways to monitor disease activity. In
this way, cell-specific carriers may reduce the length of clini-
cal trials (96 weeks for simtuzumab in PSC patients [5] and
240 weeks in a planned study in patients with NASH [7]),
which is one of the largest issues in the development of new
drugs against liver fibrosis [4, 87]. Upon entering the era of
biologicals and personalized medicine, nanomedicines pro-
vide important opportunities to treat complex diseases of liver
fibrosis.
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